ID
45223
Description
Principal Investigator: James R. Downing, MD, Dept. of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA MeSH: Acute Myeloid Leukemia https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000414 Pediatric *de novo* acute myeloid leukemia (AML) is a heterogeneous disease that can be divided into clinically distinct subtypes based on the presence of specific chromosomal abnormalities or gene alterations. One of the best characterized subtypes of AML involves leukemias with alterations of the core-binding factor (CBF)-complex, which comprises the FAB subtypes M2 and M4Eo and associates with a favorable outcome. Patients with the AML M2 subtype harbor a translocation between chromosomes 8 and 21 [t(8;21)] that yields the chimeric fusion gene *RUNX1(AML1)-RUNX1T1(ETO)*, while patients with AML M4Eo express the chimeric fusion gene *CBFβ-SMMHC(MYH11)* as a result of an inversion/translocation event of chromosome 16 [inv(16)/t(16;16)]. In an effort to define the total complement of genetic changes in CBF-leukemia, we performed paired-end whole genome sequencing (WGS) on diagnostic leukemia blasts and matched germ line samples from 17 pediatric CBF-leukemia patients using the Illumina platform. Somatic alterations, including single nucleotide variations (SNVs) and structural variations (SVs), including insertions, deletions, inversions, and inter- and intra-chromosomal rearrangements, were detected using complementary analysis pipelines (Bambino, CREST and CONSERTING). Recurrent screening of identified mutations will be performed in a cohort of approximately 94 cases of CBF-leukemias.
Lien
Mots-clés
Versions (2)
- 29/07/2022 29/07/2022 - Simon Heim
- 12/10/2022 12/10/2022 - Adrian Schulz
Détendeur de droits
James R. Downing, MD, Dept. of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA
Téléchargé le
12 octobre 2022
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
dbGaP phs000414 Whole Genome Sequencing of CBF-Leukemia
Sample ID, tumor status, body site where sample was collected, analyte type, histological type of samples, and primary tumor location obtained from participants with leukemia and involved in the "Whole genome sequencing of core-binding factor leukemia" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, subject source, subject source ID, consent groups, and affection status of participants with leukemia and involved in the "Whole genome sequencing of core-binding factor leukemia" project.
- Sample ID, subject ID, sample source, sample source ID, and sample use variables obtained from participants with leukemia and involved in the "Whole genome sequencing of core-binding factor leukemia" project.
- Sample ID, tumor status, body site where sample was collected, analyte type, histological type of samples, and primary tumor location obtained from participants with leukemia and involved in the "Whole genome sequencing of core-binding factor leukemia" project.
Similar models
Sample ID, tumor status, body site where sample was collected, analyte type, histological type of samples, and primary tumor location obtained from participants with leukemia and involved in the "Whole genome sequencing of core-binding factor leukemia" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, subject source, subject source ID, consent groups, and affection status of participants with leukemia and involved in the "Whole genome sequencing of core-binding factor leukemia" project.
- Sample ID, subject ID, sample source, sample source ID, and sample use variables obtained from participants with leukemia and involved in the "Whole genome sequencing of core-binding factor leukemia" project.
- Sample ID, tumor status, body site where sample was collected, analyte type, histological type of samples, and primary tumor location obtained from participants with leukemia and involved in the "Whole genome sequencing of core-binding factor leukemia" project.
C1299222 (UMLS CUI [1,2])